KR910700075A - 가교된 항체(Cross-linked antibodies)와 그들의 제조방법 - Google Patents

가교된 항체(Cross-linked antibodies)와 그들의 제조방법

Info

Publication number
KR910700075A
KR910700075A KR1019900702231A KR900702231A KR910700075A KR 910700075 A KR910700075 A KR 910700075A KR 1019900702231 A KR1019900702231 A KR 1019900702231A KR 900702231 A KR900702231 A KR 900702231A KR 910700075 A KR910700075 A KR 910700075A
Authority
KR
South Korea
Prior art keywords
antibody
conjugate
interchain
bridge
group
Prior art date
Application number
KR1019900702231A
Other languages
English (en)
Inventor
케이스 린드 스테펀
밀러 케네스
엔드류 밀리칸 토마스
Original Assignee
원본미기재
셀텍크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 셀텍크 리미티드 filed Critical 원본미기재
Publication of KR910700075A publication Critical patent/KR910700075A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

내용 없음.

Description

가교된 항체(Cross-linked antibodies)와 그들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 한개 이상의 리포터기나 효과기를 포함하는 체인간 브리지를 가지는 표지된 항체를 포함하고, 상기 브리지는 항체의 항원 결합영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착됨을 특징으로 하는 가교된 항체 접합체.
  2. 제1항에 있어서, 상기 브리징 부위는 아미노산 잔기의 측쇄에 존재하는 아미노기, 설피드릴기, 카르복실기, 페놀기이거나 또는 다른 방향족 혹은 헤테로 방향족 관능기임을 특징으로 하는 접합체.
  3. 제2항에 있어서, 상기 브리징 부위는 시스테인 잔기의 측쇄에 존재하는 설피디릴기임을 특징으로 하는 접합체.
  4. 제3항에 있어서, 시스테인 잔기는 힌지영역내에서 각 중쇄에 존재함을 특징으로 하는 접합체.
  5. 제4항에 있어서, 시스테인 잔기는 오직 힌지영역내에 존재하는 시스테인 잔기임을 특징으로 하는 접합체.
  6. 상기의 어느 한항에 있어서, 항체는 재조합 항체임을 특징으로 하는 접합체.
  7. 상기의 어느 한항에 있어서, 항체는 항체 단편임을 특징으로 하는 접합체.
  8. 제7항에 있어서, 단편은 F(ab′) 단편임을 특징으로 하는 접합체.
  9. 전항의 어느 한 항에 있어서, 체인간 브리지는 비디설파이드 체인간 브리지임을 특징으로 하는 접합체.
  10. 전항의 어느 한 항에 있어서, 체인간 브리지는 호모-혹은 헤테로 기능의 가교시약의 잔기임을 특징으로 하는 접합체.
  11. 제10항에 있어서, 리셉터기나 효과기는 NMR 혹은 ESR 스펙트로스코피, 약물학적 시약, 효소 혹은 호르몬에 의해 탐지될 수 있는 방사성 핵종, 킬레이트된 금속, 형광화합물임을 특징으로 하는 접합체.
  12. 제11항에 있어서, 리포터기나 효과기는 방사성 핵종이나 킬레이트된 금속임을 특징으로 하는 접합체.
  13. 제12항에 있어서, 방사성 핵종은 방사성 요오드임을 특징으로 하는 접합체.
  14. 제12항에 있어서, 킬레이트된 금속은 배위수 2-8개를 가진 2가 혹은 3가의 양이온 금속의 킬레이트나 포리덴테이트 킬레이트 시약임을 특징으로 하는 접합체.
  15. 제14항에 있어서, 폴리덴테이트 킬레이트 시약은 환상 혹은 비환상의 폴리아민, 폴리에테르, 폴리아마이드, 포르피린이나 카보사이클릭 유도체임을 특징으로 하는 접합체.
  16. 제15항에 있어서, 비환상 폴리아민은 폴리아미노 카로복실산임을 특징으로 하는 접합체.
  17. 제15항에 있어서, 환상 폴리아민은 환상 트리-아자 혹은 테트라-아자 유도체임을 특징으로 하는 접합체.
  18. 한개 이상의 리셉터기나 효과기를 포함하고 한개 이상의 체인간 브리지를 가지는 항체 분자를 포함하고, 상기 브리지는 한개 이상의 약학적으로 허용 가능한 담체나 부형제와 함께 항체의 항원 결합영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착된 약학적 조성물.
  19. 한개 이상의 리셉터기나 효과기를 포함하는 한개 이상의 체인간 브리지를 가지는 항체 분자를 포함하고, 상기 브리지는 항체의 항원 결합영역의 외측에 위치한 한개 이상의 브리징 부위에서 각 체인에 부착되고 항체와 반응하는 가교시약을 포함함을 특징으로 하는 항체 접합체의 제조방법.
  20. 제19항에 있어서, 항체는 가교시약보다 과잉의 농도로 존재함을 특징으로 하는 방법.
  21. 항체 접합체는 한개 이상의 리셉터기나 효과기를 포함하는 한개 이상의 체인간 브리지를 가지는 항체분자를 포함하고, 상기 브리지는 항체의 항원결합 영역의 외측에 한개 이상의 브리징 부위에서 각 체인에 부착되는 상기 항체 접합체를 사용함을 특징으로 하는 인간이나 동물을 치료나 진단하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702231A 1989-02-10 1990-02-12 가교된 항체(Cross-linked antibodies)와 그들의 제조방법 KR910700075A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898903022A GB8903022D0 (en) 1989-02-10 1989-02-10 Chemical compounds
GB89030225 1989-02-10
PCT/GB1990/000213 WO1990009195A1 (en) 1989-02-10 1990-02-12 Cross-linked antibodies and processes for their preparation

Publications (1)

Publication Number Publication Date
KR910700075A true KR910700075A (ko) 1991-03-13

Family

ID=10651472

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702231A KR910700075A (ko) 1989-02-10 1990-02-12 가교된 항체(Cross-linked antibodies)와 그들의 제조방법

Country Status (16)

Country Link
EP (1) EP0384624B1 (ko)
JP (1) JP2975676B2 (ko)
KR (1) KR910700075A (ko)
AT (1) ATE123952T1 (ko)
AU (1) AU632536B2 (ko)
CA (1) CA2026312A1 (ko)
DE (1) DE69020182T2 (ko)
FI (2) FI904975A0 (ko)
GB (2) GB8903022D0 (ko)
HU (1) HUT56288A (ko)
IE (1) IE67320B1 (ko)
IL (1) IL93361A0 (ko)
NO (1) NO904367L (ko)
NZ (1) NZ232490A (ko)
WO (1) WO1990009195A1 (ko)
ZA (1) ZA90983B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
JP2005181192A (ja) * 2003-12-22 2005-07-07 Tacmina Corp 残留塩素濃度測定方法
WO2005115436A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
DE602005025911D1 (de) * 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
DE102005034950A1 (de) 2005-07-22 2007-02-01 Tesa Ag Abroller für die Herstellung eines Klebebandschlauchs
DE602007009954D1 (de) 2006-03-22 2010-12-02 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid-targets
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
WO1990009195A1 (en) 1990-08-23
IE900494L (en) 1990-08-10
FI904975A0 (fi) 1990-10-09
IE67320B1 (en) 1996-03-20
HU901641D0 (en) 1991-03-28
GB2237020B (en) 1993-04-14
GB8903022D0 (en) 1989-03-30
IL93361A0 (en) 1990-11-29
ZA90983B (en) 1991-10-30
DE69020182T2 (de) 1995-11-30
NZ232490A (en) 1992-09-25
ATE123952T1 (de) 1995-07-15
EP0384624A2 (en) 1990-08-29
NO904367D0 (no) 1990-10-09
JPH03504644A (ja) 1991-10-09
EP0384624B1 (en) 1995-06-21
HUT56288A (en) 1991-08-28
AU5047590A (en) 1990-09-05
GB9021894D0 (en) 1990-11-28
AU632536B2 (en) 1993-01-07
CA2026312A1 (en) 1990-08-11
GB2237020A (en) 1991-04-24
FI904974A0 (fi) 1990-10-09
EP0384624A3 (en) 1990-11-14
DE69020182D1 (de) 1995-07-27
JP2975676B2 (ja) 1999-11-10
NO904367L (no) 1990-12-06

Similar Documents

Publication Publication Date Title
KR910700076A (ko) 가교된 항체(Cross-linked antibodies)와 그들의 제조방법
KR910700075A (ko) 가교된 항체(Cross-linked antibodies)와 그들의 제조방법
JPH0647557B2 (ja) 放射性標識抗体フラグメント
KR930701490A (ko) 3가 및 4가 단일특이성 항원결합 단백질
JPS631972A (ja) 放射性標識蛋白質のためのカツプリング剤
DE69315213D1 (de) Photoaktivierung von proteinen zu konjugationszwecken
US5354554A (en) Crosslinked antibodies and processes for their preparation
Schott et al. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments
RU98115277A (ru) Антитела с уменьшенным суммарным положительным зарядом
Wilbur et al. Monoclonal antibody Fab'fragment crosslinking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F (ab') 2 fragments
Hainsworth et al. Novel preparation and characterization of a trastuzumab–streptavidin conjugate for pre-targeted radionuclide therapy

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid